Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Acute myeloid leukemia treated by Filgrastim as an adjunct to chemotherapy
April 21st, 2006
Acute myeloid leukemia (AML) treatment could be supported by use of Filgrastim as an adjunct to chemotherapy. "We previously reported the results of a double-blind, placebo-controlled study of Filgrastim in patients with de novo AML undergoing induction and consolidation chemotherapy. The study demonstrated that Filgrastim was effective and well tolerated and had no impact on complete remission or survival," scientists in Germany reported. "We now report follow-up data on these patients, assessing long-term effects with emphasis on prognostic indicators." The team explained, "After a median follow-up of 7 years, 434 (83%) patients were dead, 73 (14%)...
Source: Science Letter (2006-04-21)
|
